James Healy is a physician-scientist with dual M.D. and Ph.D. from Stanford who brings deep immunology expertise to his venture investing at Sofinnova, particularly in evaluating complex therapeutics like in vivo CAR-T for autoimmune disease. He combines hands-on investing with active board leadership across multiple companies, often staying involved from early stages through critical clinical and financing milestones over his roughly two-decade career.